← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #441 OF 1,000 MOST-CITED

ELDU without veterinary client-patient relationship

FDA cited this observation 44 times across 44 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Veterinary Medicine44
BY FISCAL YEAR
FY20252
FY20241
FY20233
FY20223
FY20204
FY20197
FY20189
FY201715

How FDA worded it — real examples

You used an animal drug in a manner contrary to label directions without benefit of a valid veterinary/client/patient relationship.

David J. Frahm, Sr · Edgar, Wisconsin · Veterinary Medicine · 2025-08-07

You used an animal drug in a manner contrary to label directions without benefit of a valid veterinary/client/patient relationship.

Alvin Zimmerman · Lewisburg, Pennsylvania · Veterinary Medicine · 2025-02-04

You used an animal drug in a manner contrary to label directions without benefit of a valid veterinary/client/patient relationship.

Blake Malone · Ottertail, Minnesota · Veterinary Medicine · 2024-03-06

You used an animal drug in a manner contrary to label directions without benefit of a valid veterinary/client/patient relationship.

Blaken Farms · Melrose, Wisconsin · Veterinary Medicine · 2023-07-19

You used an animal drug in a manner contrary to label directions without benefit of a valid veterinary/client/patient relationship.

I.G. Raak · Jasper, Minnesota · Veterinary Medicine · 2022-11-17

You used an animal drug in a manner contrary to label directions without benefit of a valid veterinary/client/patient relationship.

Neil Martin · New Paris, Indiana · Veterinary Medicine · 2022-11-02

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Veterinary industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →